The Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients

Size: px
Start display at page:

Download "The Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients"

Transcription

1 The Journal of International Medical Research 2003; 31: The Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients S VATANSEVER 1, V AKKAYA 1, O ERK 1, Ş ÖZTÜRK 1, MA KARAN 1, N SALMAYENLI 2, C TAŞÇIOĞLU 1 AND K GÜLER 1 1 Department of Internal Medicine, Division of Emergency Medicine, and 2 Department of Biochemistry, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey This study compares the diagnostic value of troponin T (TnT) and myoglobin with creatinine kinase (CK) for myocardial infarction (MI) in a tertiary care centre in a developing nation. The study group comprised 33 acute myocardial infarction patients and 27 healthy controls. Receiver operating characteristic curves for TnT, myoglobin and CK were drawn and areas under the curve calculated. At admission, myoglobin levels had greater diagnostic sensitivity than TnT or CK levels. After 2 h, myoglobin and TnT had equal sensitivity and specificity, whereas CK still had lower sensitivity than myoglobin and TnT. After 4 h there was no difference between the tests. It was concluded that myoglobin levels on admission and TnT at 2 h had the greatest diagnostic rate, whereas all the tests were similar after 4 h for MI. KEY WORDS: MYOGLOBIN; TROPONIN T; ACUTE MYOCARDIAL INFARCTION; RECEIVER OPERATING CHARACTERISTIC CURVES; TURKEY Introduction The diagnosis of myocardial infarction (MI) depends on evidence of myocyte necrosis provided by biochemical tests, clinical examination and electrocardiography (ECG). 1,2 The enzymes classically used as markers of myocyte necrosis are creatinine kinase (CK), aspartate aminotransferase and lactic dehydrogenase, which reach diagnostic levels long after the acute event and are not specific to myocardial damage. Hence, they are not suitable for early diagnosis. 3 Diagnosis or exclusion of MI as early as possible after admission to an emergency unit is essential for good prognosis. New and expensive biochemical tests have been developed and are used for this purpose. Troponin T (TnT), a regulatory protein of myocyte contractility specific to heart muscle was found to be a specific and sensitive marker of cardiac myocyte necrosis. 4 Myoglobin, another protein present in myocytes, has been found to peak early and hence be useful in the early diagnosis of MI, though with a lower specificity. 5 Nations with poor resources may have patient profiles different to those of developed countries; for example, the mean time of arrival at a medical facility may be longer and the clinical spectrum of the patients may show less variability. This may 76

2 reduce the need for expensive tests in the diagnosis of MI. The purpose of this study was to compare the diagnostic value of TnT and myoglobin with CK for MI in our local population in Turkey. Patients and methods PATIENTS AND CLINICAL EXAMINATION Patients with acute MI diagnosed by clinical presentation and ECG in the Emergency Unit of the University of Istanbul, Istanbul Faculty of Medicine, Turkey, were recruited to the study group. All had ST segment elevation greater than 1 mm in two or more contiguous leads on the ECG and diffuse retrosternal five dermatome chest pain. Time from onset of chest pain to admission and admission to diagnosis were noted. Venous blood samples were taken on admission and after 2 h, 4 h, 12 h and 24 h. The control group comprised members of the health profession, matched for age and gender. Blood samples were taken once after a h fast. All patients were treated in accordance with the requirements of Good Clinical Practice. The Declaration of Helsinki s recommendations for guiding physicians in biomedical research involving human subjects were followed. LABORATORY ANALYSES Measurement of CK enzyme activity was done on a Cobas-Integra 700 automation system (F Hoffman-La Roche Diagnostics, Basel, Switzerland), using commercial kits (Roche Diagnostic Kit No , Mannheim, Germany). The measurement interval, intraassay and inter-assay variability for CK were IU/l, 0.77% and 1.8%, respectively. The blood samples used for TnT and myoglobin measurement were centrifuged and the supernatant stored at 40 C. TnT and myoglobin were measured by electrochemiluminescence immune assay using a Roche Diagnostic Elecsys 2010 immune-assay device (F Hoffman-La Roche Diagnostics, Basel, Switzerland) and a commercial kit (Roche Diagnostic Kit No for myoglobin, No for TnT, Mannheim, Germany). The measurement interval, intra-assay and inter-assay variability were ng/ml, 1.1% and 5.4% for TnT and ng/ml, 2.9% and 3.6% for myoglobin, respectively. STATISTICAL ANALYSIS The receiver operating characteristic (ROC) curves for CK, TnT and myoglobin were drawn and areas under the curve (AUC) and their SEs derived using statistical package SPSS for Windows 10.0 (SPSS Inc., Illinois, USA). ROC curves display the relationship between sensitivity and specificity for tests which have continuous outcomes. True-positive (sensitivity) rates are plotted against false-positive (1 specificity) rates, and the closer the curve is to the upper left corner, the more accurate the test. Diagnostic tests can be compared by visually analysing the ROC curves or, more accurately, by computing the AUC and using a modified Wilcoxon rank sum procedure as follows. The performance of different markers obtained from the same patient population was determined by comparing the area under the ROC using a method described by Hanley and McNeil. 6 The method consists of computing a ratio z using the equation: z = (A 1 A 2 )/ (SE 12 + SE 22 2* r * SE 1 *SE 2 ) where A 1 and A 2 are areas under the ROCs, SE 1 and SE 2 are the corresponding SEs and r is the estimated correlation coefficient between A 1 and A 2. The z values were estimated for various combinations of the indices, and the statistical significance (two-tailed P-value) determined from the standard z distribution tables. Subgroup analyses for onset of chest pain < 6 h or > 6 h before admission were undertaken using the equation: 77

3 z = (A 1 A 2 )/ (SE 12 + SE 22 ). The cut-off point of the test was taken as the point of minimum value of the function: (1 sensitivity) 2 + (1 specificity) 2. The results were considered statistically significant if P < 0.05 (z 1.96). Results The study group comprised 33 patients (29 men, four women, mean age 51 ± 11 years) and the control group 27 people (24 men, three women, mean age 51 ± 12 years). The location of the MI was acute anterior in 16 cases (48%), inferior and right ventricular in three (9%), inferior in nine (27%), inferoposterior in three (9%) and high lateral in two (6%) patients. Time from chest pain to diagnosis was 6.5 ± 4.6 h, and 19 patients (58%) arrived in the department within 6 h of the onset of chest pain. The changes in CK, TnT and myoglobin levels 0 h, 2 h, 4 h, 12 h and 24 h after admission are given in Figs 1 and 2. Myoglobin levels reached maximum 4 h after admission and had decreased abruptly by 12 h and 24 h after admission without reaching control levels. Maximum levels for CK and TnT were reached 12 h after admission and had started to decline by 24 h. Sensitivity and specificity of the tests at admission and 2 h later are given in Table 1. The most sensitive test at admission was myoglobin, but after 2 h TnT and myoglobin were equally sensitive. AUCs and SE for CK, TnT and myoglobin are reported in Table 2. On admission, myoglobin had greater diagnostic sensitivity than TnT (P = 0.034) or CK (P = 0.043; Fig. 3). The AUC curve for CK was greater than for TnT, but it did not reach Means of creatinine kinase and myoglobin with their 95% confidence interval Creatinine kinase Myoglobin 0 Controls Admission 2 h 4 h 12 h 24 h FIGURE 1: Changes in the mean levels of creatinine kinase enzyme activity and myoglobin, measured in patients admitted with acute myocardial infarction and controls. Blood was drawn from patients for these measurements at admission, and 2 h, 4 h, 12 h and 24 h after admission. Control blood was drawn after a h fast. Creatinine levels peaked after 12 h, while myoglobin peaked after 4 h 78

4 6 Mean and 95% confidence interval of troponin T Controls Admission 2 h 4 h 12 h 24 h FIGURE 2: Changes in troponin T levels measured in patients admitted with acute myocardial infarction and controls. Levels were measured in blood drawn from patients at admission and 2 h, 4 h, 12 h and 14 h after admission. Control blood was drawn after a h fast. Troponin T levels peaked after 12 h statistical significance. Tests done 2 h after admission showed that TnT had the greatest diagnostic sensitivity, compared with CK (P = 0.003) and myoglobin. The difference between CK and myoglobin was still significant 2 h after admission (P = 0.04; Fig. 4). After 4 h, there was no difference in the diagnostic sensitivities between the tests, although the sensitivity of myoglobin began to decline. When patients were grouped according to duration of chest pain prior to admission (> 6 h or < 6 h), AUC for admission levels of TnT (Table 3; P = 0.33) and myoglobin were lower in patients admitted earlier, but did not reach statistical significance. Two hours after admission, there was no difference between the groups for TnT or myoglobin. Results obtained 4 h after admission showed no difference between the groups according to the duration of chest pain (Table 3). However, when the diagnostic accuracy of the tests (comparison of the AUC of the respective ROCs) was compared at TABLE 1: Sensitivity and specificity of creatinine kinase, troponin T and myoglobin at admission and 2 h after admission Admission 2 h after admission Sensitivity (%) Specificity (%) Sensitivity(%) Specificity (%) Creatinine kinase Troponin T Myoglobin

5 TABLE 2: Areas under the curve and their standard errors of creatinine kinase, troponin T and myoglobin according to time from admission Time from admission Creatinine kinase Troponin T Myoglobin 0 h ± ± ± h ± ± ± h ± ± ± h ± ± ± h ± ± ± admission according to duration of chest pain before admission, myoglobin seemed to be a more valuable test than either TnT (P = and P = 0.09, respectively) or CK (P = 0.12 and P = 0.012). Discussion The purpose of this study was to examine the diagnostic accuracy of the laboratory tests according to time from patient admission. As Sensitivity Source of the curve Reference Myoglobin Troponin T Creatinine kinase Specificity FIGURE 3: Receiver operating characteristic curves showing the relationship between specificity and sensitivity, drawn for creatinine kinase, troponin T and myoglobin at the time of admission. The closer the curve is to the upper left corner, the more accurate the test 80

6 Sensitivity Source of the curve Reference Myoglobin Troponin T Creatinine kinase Specificity FIGURE 4: Receiver operating characteristic curves showing the relationship between specificity and sensitivity, drawn for creatinine kinase, troponin T and myoglobin 2 h after admission. The closer the curve is to the upper left corner, the more accurate the test seen in Table 4, the cost of the tests in Turkey differs by an order of one, which compels their use in a rational way. The working hypothesis was that the time from the start of pain to patient admission would be longer in Turkey than elsewhere, obviating the advantage of the newer diagnostic tests. It was found, however, that on admission, the diagnostic rate for myoglobin was higher than either TnT or CK, and at 2 h after TABLE 3: Areas under the curve and their SEs for creatinine kinase, troponin T and myoglobin according to time from admission and the duration of chest pain on admission Duration of chest Time from admission pain Creatinine kinase Troponin T Myoglobin < 6 h > 6 h < 6 h > 6 h < 6 h > 6 h 0 h ± ± ± ± ± ± h ± ± ± ± ± ± h ± ± ± ± ± ± h ± ± ± ± ± ± h ± ± ± ± ± ±

7 TABLE 4: Kit costs for myocardial enzymes in Turkey Kit costs per Enzyme examination (US$) Creatinine kinase 0.32 Myoglobin 2.48 Troponin T 4.18 admission myoglobin had equivalent diagnostic sensitivity to TnT. The higher diagnostic rate of myoglobin at admission may be explained by its release kinetics after myocardial damage, 7 and the timing of enzyme rise was consistent with findings in other countries The ROC sensitivity and specificity curves seemed to be shifted to the left, i.e. to an earlier time from admission. This may be due to systemic underestimation of the time of onset of cardiac pain by the patients, or may be caused by comparing patients and controls from the two extremes sicker patients with MI versus normal controls. In our patient population, if the time estimations are correct, the favourable outcome of the newer tests may be artifactual due to early admission of patients to our centre, and may not be representative of the care received by Turkish MI patients generally. The only data on the patient population admitted to coronary care units with a diagnosis of MI in Turkey come from the Turkish Myocardial Infarction Registry Study (TÜMAR) (unpublished), undertaken between August 1998 and August The registry contains details of 3358 cases of acute MI presenting to 92 medical centres from 23 cities. In that study, 83% of patients had ST elevation on admission and 71% were admitted within 6 h of onset of chest pain (median 3.5 h). This compares with all our patients having ST elevation but fewer being admitted within 6 h of chest pain (median = 4.7 h), suggesting that our patient population is representative of MI patients admitted to coronary care units in Turkey. Comparing the data from our study with time from chest pain to admission figures from the ENACT 11 (65% within 12 h, 116 patients from Turkey) and PRAIS-UK 12 (median 3 h [IQR ]) studies suggests that the time from chest pain to admission is similar in Turkey to elsewhere. Can the results from our study be extrapolated to cases admitted with equivocal ECG findings? Our study population represents 83% of the patients admitted to coronary care units in Turkey according to the TÜMAR data, but patients admitted with equivocal ECG findings represent the minority of coronary care patients in Turkey. The ENACT study also states that the final diagnosis is MI in 20% of patients with a provisional diagnosis of acute coronary syndrome and 10% of patients with a normal ECG. 11 We are confident that if MI is not apparent on admission, follow-up and myoglobin analysis for 4 h after admission would give the best rate of diagnosis. For patients with equivocal ECG findings, myocardial necrosis may develop during the follow-up period with concomitant increase in biochemical markers for up to 12 h after admission, which decreases the validity of this extrapolation. 13 To conclude, in our Turkish population at admission, analysis of myoglobin had the greatest diagnostic rate for MI. Myoglobin was equivalent to TnT 2 h after admission and all tests were equivalent 4 h after admission. Received for publication 20 November 2002 Accepted 20 December 2002 Copyright 2003 Cambridge Medical Publications 82

8 References 1 The Joint European Society of Cardiology/ American College of Cardiology Committee: Myocardial infarction redefined a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J 2000; 21: Panteghini M: Biochemical assessment of myocardial damage with new diagnostic tools. Cardiologia 1999; 44: Penttila I, Penttila K, Rantanen T: Laboratory diagnosis of patients with acute chest pain. Clin Chem Lab Med 2000; 38: Lang K, Borner A, Figulla HR: Comparison of biochemical markers for the detection of minimal myocardial injury: superior sensitivity of cardiac troponin-t ELISA. J Intern Med 2000; 247: Panteghini M, Apple FS, Christenson RH, Dati F, Mair J, Wu AH: Use of biochemical markers in acute coronary syndromes. IFCC Scientific Division, Committee on Standardization of Markers of Cardiac Damage. International Federation of Clinical Chemistry. Clin Chem Lab Med 1999; 37: Hanley J, McNeil BJ: A method of comparing the areas under receiver operating characteristics curves derived from the same cases. Radiology 1983; 148: Mair J: Tissue release of cardiac markers: from physiology to clinical applications. Clin Chem Lab Med 1999; 37: Jurlander B, Clemmensen P, Wagner GS, Grande P: Very early diagnosis and risk stratification of patients admitted with suspected acute myocardial infarction by the combined evaluation of a single serum value of cardiac troponin-t, myoglobin, and creatinine kinase MB mass. Eur Heart J 2000; 21: Panteghini M, Pagani F, Bonetti G: The sensitivity of cardiac markers: an evidencebased approach. Clin Chem Lab Med 1999; 37: Hudson MP, Christenson RH, Newby LK, Kaplan AL, Ohman EM: Cardiac markers: point of care testing. Clin Chim Acta 1999; 284: Fox KAA, Cokkinos DV, Decker J, Keil U, Maggioni A, Steg G on behalf of the ENACT investigators: The ENACT Study: a pan- European survey of acute coronary syndromes. Eur Heart J 2000; 21: Collinson J, Flather MD, Fox KAA, Findley I, Rodrigues E, Dooley P, et al. for the PRAIS-UK Investigators: Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Eur Heart J 2000; 21: Jernberg T, Lindahl B, Wallentin L: The combination of a continuous 12-lead ECG and troponin T. Eur Heart J 2000; 21: Address for correspondence Dr S Vatansever Kaptanpaşa mah, Halit Ziya Türkkan Sok, Famas Blokları B blok 6/20, Şişli-İstanbul, Turkey. sezai@istanbul.edu.tr 83

Pharmacologyonline 2: (2010) Newsletter Kakadiya and Shah

Pharmacologyonline 2: (2010) Newsletter Kakadiya and Shah ROLE OF CREATINE KINASE MB AND LACTATE DEHYDROGENASE IN CARDIAC FUNCTION A REVIEW Jagdish Kakadiya*, Nehal Shah Department of Pharmacology, Dharmaj Degree Pharmacy College, Petlad- Khambhat Road, Dharmaj,

More information

BIOCHEMICAL INVESTIGATIONS IN THE DIAGNOSTICS OF CARDIOVASCULAR DISORDERS. As. MARUSHCHAK M.I.

BIOCHEMICAL INVESTIGATIONS IN THE DIAGNOSTICS OF CARDIOVASCULAR DISORDERS. As. MARUSHCHAK M.I. BIOCHEMICAL INVESTIGATIONS IN THE DIAGNOSTICS OF CARDIOVASCULAR DISORDERS As. MARUSHCHAK M.I. Heart attack symptoms Acute MI Measurement of cardiac enzyme levels Measure cardiac enzyme levels at regular

More information

Rapid detection of myocardial infarction with a sensitive troponin test Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R.

Rapid detection of myocardial infarction with a sensitive troponin test Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R. Rapid detection of myocardial infarction with a sensitive troponin test Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R. Published in: American Journal of Clinical Pathology DOI: 10.1309/AJCPA4G8AQOYEKLD

More information

Cardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray

Cardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray Cardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Describe the acute

More information

Use of Biomarkers for Detection of Acute Myocardial Infarction

Use of Biomarkers for Detection of Acute Myocardial Infarction Use of Biomarkers for Detection of Acute Myocardial Infarction Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine

More information

Troponin when is an assay high sensitive?

Troponin when is an assay high sensitive? Troponin when is an assay high sensitive? Professor P. O. Collinson MA MB BChir FRCPath FRCP edin MD FACB EurClin Chem Consultant Chemical Pathologist and Professor of Cardiovascular Biomarkers, Departments

More information

High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr.

High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr. High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr. Marcel El Achkar Chairperson of Laboratory department Nini Hospital Lecturer

More information

Papers in Press. Published March 23, 2007 as doi: /clinchem

Papers in Press. Published March 23, 2007 as doi: /clinchem Papers in Press. Published March 23, 2007 as doi:10.1373/clinchem.2006.084715 The latest version is at http://www.clinchem.org/cgi/doi/10.1373/clinchem.2006.084715 Clinical Chemistry 53:4 547 551 (2007)

More information

Evaluation of the optimal myocardial infarction cutoff for the PATHFAST Troponin I assay of Mitsubishi Kagaku Iatron (MKI)

Evaluation of the optimal myocardial infarction cutoff for the PATHFAST Troponin I assay of Mitsubishi Kagaku Iatron (MKI) Evaluation of the optimal myocardial infarction cutoff for the PATHFAST Troponin I assay of Mitsubishi Kagaku Iatron (MKI) Principal Investigator: Priv. Doz. Dr. med Dirk Peetz Institute of Clinical Chemistry

More information

Original Article ABSTRACT. Kiumars Ahmadi 1 PhD, Fahimeh Dadgari 1 MS, Mohammad Reza Safarinejad 2 MD

Original Article ABSTRACT. Kiumars Ahmadi 1 PhD, Fahimeh Dadgari 1 MS, Mohammad Reza Safarinejad 2 MD Original Article The most sensitive double-marker method of cardiac isoenzymes of creatinine kinase, troponin I, and myoglobin in different time periods for diagnosing acute myocardial infarction Kiumars

More information

hs-c Tn I high sensitivity troponin I <17 min

hs-c Tn I high sensitivity troponin I <17 min hs-c Tn I high sensitivity troponin I IFCC & ESC compliant 0/ h NSTEMI rule-out / rule-in algorithm POCT whole blood/plasma Results in < 7 minutes

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Rubini Giménez M, Twerenbold R, Boeddinghaus J, et al. Clinical effect of sex-specific cutoff values of high-sensitivity cardiac troponin T in suspected myocardial infarction.

More information

Comparison between Certain Parameters for Diagnosis of Acute Myocardial Infarction

Comparison between Certain Parameters for Diagnosis of Acute Myocardial Infarction Comparison between Certain Parameters for Diagnosis of Acute Myocardial Infarction Muthear N. Dawood * Akram J. Ahmed ** ABSTRACT Background and Objective: The identification and diagnosis of acute myocardial

More information

Setting The setting was secondary care. The economic study was carried out in Hong Kong.

Setting The setting was secondary care. The economic study was carried out in Hong Kong. The diagnostic value and cost-effectiveness of creatine kinase-mb, myoglobin and cardiac troponin-t for patients with chest pain in emergency department observation ward Choi Y F, Wong T W, Lau C C Record

More information

13. RECOMMENDATIONS ON USE OF BIOCHEMICAL MARKERS IN ACUTE CORONARY SYNDROME: IFCC PROPOSALS

13. RECOMMENDATIONS ON USE OF BIOCHEMICAL MARKERS IN ACUTE CORONARY SYNDROME: IFCC PROPOSALS 13. RECOMMENDATIONS ON USE OF BIOCHEMICAL MARKERS IN ACUTE CORONARY SYNDROME: IFCC PROPOSALS Prof. Mauro Panteghini, MD, Ph.D. Chairman of the IFCC Committee on Standardization of Markers of Cardiac Damage

More information

EDUCATIONAL COMMENTARY UNDERSTANDING THE BENEFITS AND CHALLENGES OF HIGH- SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS

EDUCATIONAL COMMENTARY UNDERSTANDING THE BENEFITS AND CHALLENGES OF HIGH- SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE

More information

High Sensitivity Troponin Improves Management. But Not Yet

High Sensitivity Troponin Improves Management. But Not Yet High Sensitivity Troponin Improves Management But Not Yet Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine

More information

Comparative assessment of rapid test and routinmethods th to measurement of cardiac markers in patients with acute chest pain

Comparative assessment of rapid test and routinmethods th to measurement of cardiac markers in patients with acute chest pain Comparative assessment of rapid test and routinmethods th to measurement of cardiac markers in patients with acute chest pain *Reza Shahsavari I, Nastou Dehkourdi II and Saeid Yazdankha III I ) Assistant

More information

P1: OTE/SPH P2: OTE BLUK084-Adams April 13, :13 PART 1. Cardiac troponins

P1: OTE/SPH P2: OTE BLUK084-Adams April 13, :13 PART 1. Cardiac troponins PART 1 Cardiac troponins 1 2 CHAPTER 1 Basics of cardiac troponin: practical aspects of assays, potential analytical confounders, and clinical interpretation Fred S. Apple Case 1 Following an episode of

More information

cobas h 232 POC system The power to make decisions in cardiac emergencies

cobas h 232 POC system The power to make decisions in cardiac emergencies cobas h 232 POC system The power to make decisions in cardiac emergencies cobas h 232 POC system Rapid results at the Point of Care (POC) Wherever and whenever you face an emergency situation, measurement

More information

JMSCR Vol 05 Issue 01 Page January 2017

JMSCR Vol 05 Issue 01 Page January 2017 JMSCR Vol Issue Page 93-943 January 27 www.jmscr.igmpublication.org Impact Factor.84 Index Copernicus Value: 83.27 ISSN (e)-2347-76x ISSN (p) 24-4 DOI: https://dx.doi.org/.83/jmscr/vi.3 Elevation of Troponin-I

More information

High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU

High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU ESC Congress 2011 Paris, France, August 27-31 KAROLA Session: Prevention: Are biomarkers worth their money? Abstract # 84698 High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients

More information

Ruling out acute myocardial infarction early with two serial creatine kinase-mb mass determinations

Ruling out acute myocardial infarction early with two serial creatine kinase-mb mass determinations European Heart Journal (1999) 20, 967 972 Article No. euhj.1998.1449, available online at http://www.idealibrary.com on Ruling out acute myocardial infarction early with two serial creatine kinase-mb mass

More information

cobas h 232 system When on the spot cardiac decisions need on the spot results in Primary Care cobas cardio

cobas h 232 system When on the spot cardiac decisions need on the spot results in Primary Care cobas cardio cobas h 232 system When on the spot cardiac decisions need on the spot results in Primary Care Is there a better pathway? Without Point of Care (POC) testing Patient presents Blood sample taken Lab collects

More information

A New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get from the Laboratory

A New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get from the Laboratory e-issn 1643-3750 DOI: 10.12659/MSM.892033 Received: 2014.07.18 Accepted: 2014.08.14 Published: 2015.01.28 A New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get

More information

Topic. Updates on Definition of Myocardial Infarction

Topic. Updates on Definition of Myocardial Infarction Topic Updates on Definition of Myocardial Infarction In the past, general consensus for MI? Definition of MI by WHO - Combination of 2 of 3 characteristics - 1. Typical Symptoms 2. Enzyme Rise 3. Typical

More information

Timing of angiography for high- risk ACS

Timing of angiography for high- risk ACS Timing of angiography for high- risk ACS Christian Spaulding, MD, PhD, FESC, FACC Cardiology Department Cochin Hospital, Inserm U 970 Paris Descartes University Paris, France A very old story. The Interventional

More information

Most patients ( 85%) who present to an emergency department

Most patients ( 85%) who present to an emergency department Ninety-Minute Exclusion of Acute Myocardial Infarction By Use of Quantitative Point-of-Care Testing of Myoglobin and Troponin I James McCord, MD; Richard M. Nowak, MD, MBA; Peter A. McCullough, MD, MPH;

More information

Current Utilities of Cardiac Biomarker Testing at POC. June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN

Current Utilities of Cardiac Biomarker Testing at POC. June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN Current Utilities of Cardiac Biomarker Testing at POC June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN 1. Discuss challenges associated with diagnosing Acute Coronary Syndromes (ACS) and Heart Failure

More information

Defining rise and fall of cardiac troponin values

Defining rise and fall of cardiac troponin values Defining rise and fall of cardiac troponin values Doable but Not Simple Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory

More information

Risk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium

Risk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium Risk Stratification of ACS Patients Frans Van de Werf, MD, PhD University of Leuven, Belgium Which type of ACS patients are we talking about to day? 4/14/2011 STEMI and NSTEMI in the NRMI registry from

More information

Heart-type fatty acid-binding protein in early diagnosis of acute myocardial infarction in comparison to sensitive troponin I

Heart-type fatty acid-binding protein in early diagnosis of acute myocardial infarction in comparison to sensitive troponin I Heart-type fatty acid-binding protein in early diagnosis of acute myocardial infarction in comparison to sensitive troponin I E. Czyz 1, S. Tzikas 1, A. Schulz 1, T. Zeller 1,3, S. Baldus 3, C. Bickel

More information

Erik J. Fransen, MSc, PhD; Jart H. C. Diris, MSc; Jos G. Maessen, MD, PhD; Wim Th. Hermens, PhD; Marja P. van Dieijen-Visser, MD, PhD

Erik J. Fransen, MSc, PhD; Jart H. C. Diris, MSc; Jos G. Maessen, MD, PhD; Wim Th. Hermens, PhD; Marja P. van Dieijen-Visser, MD, PhD Evaluation of New Cardiac Markers for Ruling Out Myocardial Infarction After Coronary Artery Bypass Grafting* Erik J. Fransen, MSc, PhD; Jart H. C. Diris, MSc; Jos G. Maessen, MD, PhD; Wim Th. Hermens,

More information

Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a sensitive troponin I assay

Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a sensitive troponin I assay Original Article Annals of Clinical Biochemistry 2015, Vol. 52(5) 543 549! The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: 10.1177/0004563215576976 acb.sagepub.com

More information

Internationally indexed journal

Internationally indexed journal www.ijpbs.net Internationally indexed journal Indexed in Chemical Abstract Services (USA), Index coppernicus, Ulrichs Directory of Periodicals, Google scholar, CABI,DOAJ, PSOAR, EBSCO, Open J gate, Proquest,

More information

Early diagnosis of acute myocardial infarction by bedside multimarker test at an emergency department in Hong Kong

Early diagnosis of acute myocardial infarction by bedside multimarker test at an emergency department in Hong Kong Hong Kong Journal of Emergency Medicine Early diagnosis of acute myocardial infarction by bedside multimarker test at an emergency department in Hong Kong CH Ho, W Cheng, G Chu, HF Ho Introduction: Cardiac

More information

ISCHEMIA MODIFIED ALBUMIN : A NOVEL MARKER FOR ACUTE CORONARY SYNDROME

ISCHEMIA MODIFIED ALBUMIN : A NOVEL MARKER FOR ACUTE CORONARY SYNDROME ISCHEMIA MODIFIED ALBUMIN : A NOVEL MARKER FOR ACUTE CORONARY SYNDROME Chawla R., Navendu Goyal, *Rajneesh Calton and Shweta Goyal Department of Biochemistry / *Cardiology, Christian Medical College, Ludhiana

More information

(1) age 60 years or older with the presence of an abnormal electrocardiogram;

(1) age 60 years or older with the presence of an abnormal electrocardiogram; National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom Bakhai A, Flather M D, Collinson J R, Stevens W, Normand C, Alemao

More information

GUIDELINES FOR TROPONIN TESTING: AN EVIDENCE-BASED APPROACH TO DIAGNOSIS AND TREATMENT OF THE ACS PATIENT

GUIDELINES FOR TROPONIN TESTING: AN EVIDENCE-BASED APPROACH TO DIAGNOSIS AND TREATMENT OF THE ACS PATIENT GUIDELINES FOR TROPONIN TESTING: AN EVIDENCE-BASED APPROACH TO DIAGNOSIS AND TREATMENT OF THE ACS PATIENT sponsored by TROPONIN OVERVIEW TROPONIN DETECTION IN NORMAL AND DISEASE STATES1 The detection of

More information

Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD

Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD Disclosures Research contracts: AstraZeneca, Bayer, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company,

More information

Prognostic significance of troponin T in acute myocardial infarction

Prognostic significance of troponin T in acute myocardial infarction International Journal of Research in Medical Sciences Prabhakaran SP et al. Int J Res Med Sci. 2017 Oct;5(10):4363-4368 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI:

More information

Peter A. Kavsak, 1* Andrew R. MacRae, 2 Glenn E. Palomaki, 3 Alice M. Newman, 4 Dennis T. Ko, 4 Viliam Lustig, 2 Jack V. Tu, 4 and Allan S.

Peter A. Kavsak, 1* Andrew R. MacRae, 2 Glenn E. Palomaki, 3 Alice M. Newman, 4 Dennis T. Ko, 4 Viliam Lustig, 2 Jack V. Tu, 4 and Allan S. Clinical Chemistry 52:11 2028 2035 (2006) Evidence-Based Laboratory Medicine and Test Utilization Health Outcomes Categorized by Current and Previous Definitions of Acute Myocardial Infarction in an Unselected

More information

Biomarkers of myocardial infarction. Dr. Mamoun Ahram Cardiovascular system, 2013

Biomarkers of myocardial infarction. Dr. Mamoun Ahram Cardiovascular system, 2013 Biomarkers of myocardial infarction Dr. Mamoun Ahram Cardiovascular system, 2013 References This lecture Hand-outs Acute Myocardial Infarction A rapid development of myocardial necrosis caused by prolonged

More information

Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction

Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung, MD, PhD; Magnus Johansson, MD, PhD; Martin Holzmann,

More information

Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction

Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung, MD, PhD; Magnus Johansson, MD, PhD; Martin Holzmann,

More information

High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial

High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2018 High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial Professor

More information

Article in press - uncorrected proof

Article in press - uncorrected proof Clin Chem Lab Med 2006;44(6):768 773 2006 by Walter de Gruyter Berlin New York. DOI 10.1515/CCLM.2006.125 2006/60 Integration between the Tele-Cardiology Unit and the central laboratory: methodological

More information

T he World Health Organization defined myocardial infarction

T he World Health Organization defined myocardial infarction 343 CARDIOVASCULAR MEDICINE Myocardial infarction redefined: the new ACC/ESC definition, based on cardiac troponin, increases the apparent incidence of infarction J L Ferguson, G J Beckett, M Stoddart,

More information

D DAVID PUBLISHING. 1. Introduction. 2. Methods. Samira Green 1, Vanessa Jessop 2, Jason Pott 2 and Tim Harris 2

D DAVID PUBLISHING. 1. Introduction. 2. Methods. Samira Green 1, Vanessa Jessop 2, Jason Pott 2 and Tim Harris 2 Journal of Health Science 2 (2014) 523-528 doi: 10.17265/2328-7136/2014.11.001 D DAVID PUBLISHING Management, Triage and Outcomes of 378 Patients Presenting to the Emergency Department with Chest Pain

More information

7/31/2018. Overview of Next Generation Cardiac Troponin T High Sensitivity. Disclosures. Course Objectives: high sensitive Troponin T assay

7/31/2018. Overview of Next Generation Cardiac Troponin T High Sensitivity. Disclosures. Course Objectives: high sensitive Troponin T assay Overview of Next Generation Cardiac Troponin T High Sensitivity Arleen Francis Medical & Scientific Liaison Roche Diagnostics 1 Disclosures Arleen Francis is an employee of Roche Diagnostics and a member

More information

Low concentrations of high-sensitivity troponin T at presentation to the

Low concentrations of high-sensitivity troponin T at presentation to the Title Page Low concentrations of high-sensitivity troponin T at presentation to the Emergency Department. Running head: Early rule-out using high-sensitivity troponin T Article Type: Letter to the Editor

More information

A. BISOC 1,2 A.M. PASCU 1 M. RĂDOI 1,2

A. BISOC 1,2 A.M. PASCU 1 M. RĂDOI 1,2 Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 THE ctntg4 PLASMA LEVELS IN RELATION TO ELECTROCARDIOGRAPHIC AND ECHOCARDIOGRAPHIC ABNORMALITIES IN

More information

Troponin Assessment. Does it Carry Clinical Message? Stefan Blankenberg. University Heart Center Hamburg

Troponin Assessment. Does it Carry Clinical Message? Stefan Blankenberg. University Heart Center Hamburg Biomarkers for Optimal Management of Heart Failure Troponin Assessment Does it Carry Clinical Message? Stefan Blankenberg University Heart Center Hamburg Congress of the European Society of Cardiology

More information

10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better

10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better 10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department

More information

Overall Changes of the Universal Myocardial Infarction Definition

Overall Changes of the Universal Myocardial Infarction Definition Overall Changes of the Universal Myocardial Infarction Definition Professor Kristian Thygesen, FESC, FACC, FAHA Aarhus University Hospital, Aarhus, DK Co-Chairman of The Global MI Task Force Declaration

More information

Ischemic Heart Disease

Ischemic Heart Disease Ischemic Heart Disease Dr Rodney Itaki Lecturer Division of Pathology University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology General Consideration Results from partial

More information

Mario Plebani University-Hospital of Padova, Italy

Mario Plebani University-Hospital of Padova, Italy Mario Plebani University-Hospital of Padova, Italy CK-MB mass assay CHF guidelines use BNP for rule out AST in AMI CK in AMI INH for CK-MB electrophoresis for CK and LD isoenzymes RIA for myoglobin WHO

More information

Analytical performance of the i-stat cardiac troponin I assay

Analytical performance of the i-stat cardiac troponin I assay Clinica Chimica Acta 345 (2004) 123 127 www.elsevier.com/locate/clinchim Analytical performance of the i-stat cardiac troponin I assay Fred S. Apple a, *, MaryAnn M. Murakami a, Robert H. Christenson b,

More information

Myocardial Infarction

Myocardial Infarction Myocardial Infarction MI = heart attack Defined as necrosis of heart muscle resulting from ischemia. A very significant cause of death worldwide. of these deaths, 33% -50% die before they can reach the

More information

High-sensitivity cardiac troponin I immunoassay reduces the chance of patient misclassification in the emergency department

High-sensitivity cardiac troponin I immunoassay reduces the chance of patient misclassification in the emergency department Original Article Page 1 of 5 High-sensitivity cardiac troponin I immunoassay reduces the chance of patient misclassification in the emergency department Giuseppe Lippi 1, Fabian Sanchis-Gomar 2,3,4, Rosalia

More information

Troponin T in patients with low grade or atypical angina

Troponin T in patients with low grade or atypical angina European Heart Journal (1998) 19, 1802 1807 Article No. hj981233 Troponin T in patients with low grade or atypical angina Identification of a high risk group for short- and long-term cardiovascular events

More information

Post Operative Troponin Leak: David Smyth Christchurch New Zealand

Post Operative Troponin Leak: David Smyth Christchurch New Zealand Post Operative Troponin Leak: Does It Really Matter? David Smyth Christchurch New Zealand Life Was Simple Once Transmural Infarction Subendocardial Infarction But the Blood Tests Were n t Perfect Creatine

More information

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor 76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class

More information

EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE

EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE

More information

VCU HEALTH SYSTEM EMERGENCY DEPARTMENT GUIDELINE

VCU HEALTH SYSTEM EMERGENCY DEPARTMENT GUIDELINE VCU HEALTH SYSTEM EMERGENCY DEPARTMENT GUIDELINE SUBJECT: Care of the Chest Pain Patient in the Emergency Department FILE SECTION: VCUHS/ED Section: Please note: Clinical Practice Guideline Evidence-based

More information

Myocardial Ischaemia National Audit Project (MINAP): Improving data capture and use across South Wales

Myocardial Ischaemia National Audit Project (MINAP): Improving data capture and use across South Wales Myocardial Ischaemia National Audit Project (MINAP): Improving data capture and use across South Wales Author Owner Document Reference Alison Turner Cardiovascular Audit and Primary Care Nurse South Wales

More information

Diagnostic effectiveness of high-sensitivity troponins

Diagnostic effectiveness of high-sensitivity troponins James Madison University JMU Scholarly Commons Physician Assistant Capstones The Graduate School Spring 5-16-2017 Diagnostic effectiveness of high-sensitivity troponins Sean R. Bodin James Madison University

More information

Table. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer.

Table. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer. Table. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer. Commercially available assays - Company/ platform(s)/ assay LoB a LoD b 99 th

More information

Impact of Troponin Performance on Patient Care

Impact of Troponin Performance on Patient Care Impact of Troponin Performance on Patient Care Linda C, Rogers PhD, DABCC, FACB Agenda Introduction Diagnosis of MI Guidelines Troponin Assay differences Classification of troponin assays Guideline acceptable

More information

Comparison of ARCHITECT chemiluminiscent microparticle immunoassay for determination of Troponin I in serum with AXYM MEIA technology

Comparison of ARCHITECT chemiluminiscent microparticle immunoassay for determination of Troponin I in serum with AXYM MEIA technology Journal of Health Sciences www.jhsci.ba Volume 1, Number 3, December 2011 Comparison of ARCHITECT chemiluminiscent microparticle immunoassay for determination of Troponin I in serum with AXYM MEIA technology

More information

National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the Use of Cardiac Markers in Coronary Artery Diseases

National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the Use of Cardiac Markers in Coronary Artery Diseases Clinical Chemistry 45:7 1104 1121 (1999) NACB National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the Use of Cardiac Markers in Coronary Artery Diseases Alan

More information

Procedures: LifeSign MI Myoglobin/CK-MB/Troponin I Test. Prepared by Date Adopted Supersedes Procedure # Review Date Revision Date Signature

Procedures: LifeSign MI Myoglobin/CK-MB/Troponin I Test. Prepared by Date Adopted Supersedes Procedure # Review Date Revision Date Signature Procedures: LifeSign MI Myoglobin/CK-MB/Troponin I Test Prepared by Date Adopted Supersedes Procedure # Review Date Revision Date Signature Distributed to # of Copies Distributed to # of Copies PRINCIPLE:

More information

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol

More information

Early risk stratification is essential in the management of

Early risk stratification is essential in the management of Cystatin C A Novel Predictor of Outcome in Suspected or Confirmed Non ST-Elevation Acute Coronary Syndrome Tomas Jernberg, MD, PhD; Bertil Lindahl, MD, PhD; Stefan James, MD, PhD; Anders Larsson, MD, PhD;

More information

Safe discharge from the cardiac emergency room with a rapid rule-out myocardial infarction protocol using serial CK-MB mass

Safe discharge from the cardiac emergency room with a rapid rule-out myocardial infarction protocol using serial CK-MB mass Heart 2001;85:143 148 143 Department of Cardiology, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands R Bholasingh R J de Winter J C Fischer R W Koster RJGPeters G T Sanders Correspondence

More information

BIOCHEMICAL EXAMINATION OF ACUTE MYOCARDIAL INFARCTION. Written by Lenka Fialová, translated by Jan Pláteník

BIOCHEMICAL EXAMINATION OF ACUTE MYOCARDIAL INFARCTION. Written by Lenka Fialová, translated by Jan Pláteník BIOCHEMICAL EXAMINATION OF ACUTE MYOCARDIAL INFARCTION 1 Structure of heart muscle Written by Lenka Fialová, translated by Jan Pláteník Heart muscle (myocardium) is a particular form of striated muscle,

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice Review consultation document Review of Clinical Guideline (CG95) Chest pain of recent onset: Assessment and diagnosis

More information

Acute coronary syndrome. Dr LM Murray Chemical Pathology Block SA

Acute coronary syndrome. Dr LM Murray Chemical Pathology Block SA Acute coronary syndrome Dr LM Murray Chemical Pathology Block SA13-2014 Acute myocardial infarction (MI) MI is still the leading cause of death in many countries It is characterized by severe chest pain,

More information

The organisation of troponin testing services in acute coronary syndromes

The organisation of troponin testing services in acute coronary syndromes Health Technology Assessment Advice 4 ~ December 2003 The organisation of troponin testing services in acute coronary syndromes Summary of recommendations NHS Quality Improvement Scotland recommends that

More information

ACCESS hstni SCIENTIFIC LITERATURE

ACCESS hstni SCIENTIFIC LITERATURE ACCESS hstni SCIENTIFIC LITERATURE 2017 2018 Table of contents Performance Evaluation of Access hstni A critical evaluation of the Beckman Coulter Access hstni: Analytical performance, reference interval

More information

DIAGNOSTICS ASSESSMENT PROGRAMME

DIAGNOSTICS ASSESSMENT PROGRAMME DIAGNOSTICS ASSESSMENT PROGRAMME Evidence overview Early rule out or diagnosis of acute myocardial infarction: High-sensitivity troponin tests (Elecsys troponin T high-sensitive, ARCHITECT STAT highsensitivity

More information

TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS

TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS European Heart Journal (2005) 26, 865 872 doi:10.1093/eurheartj/ehi187 Clinical research TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS

More information

High-sensitivity cardiac troponin and the under diagnosis of myocardial infarction in women: a prospective cohort study

High-sensitivity cardiac troponin and the under diagnosis of myocardial infarction in women: a prospective cohort study DATA SUPPLEMENT High-sensitivity cardiac troponin and the under diagnosis of myocardial infarction in women: a prospective cohort study Anoop SV Shah, 1 Megan Griffiths, 1 Kuan Ken Lee, 1 David A McAllister,

More information

Canadian Agency for Drugs and Technologies in Health. Agence canadienne des médicaments et des technologies de la santé. Supporting Informed Decisions

Canadian Agency for Drugs and Technologies in Health. Agence canadienne des médicaments et des technologies de la santé. Supporting Informed Decisions Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Optimal Use Report March 2013 Volume 2, Issue 1B Recommendations for the Use

More information

About OMICS International

About OMICS International About OMICS International OMICS International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS International hosts over 700

More information

Diagnostics consultation document

Diagnostics consultation document National Institute for Health and Care Excellence Diagnostics consultation document Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive,

More information

Dolore Toracico e Livelli di Troponina non Misurabili

Dolore Toracico e Livelli di Troponina non Misurabili Dolore Toracico e Livelli di Troponina non Misurabili Andrea Fabbri Dipartimento di Emergenza Presidio Ospedaliero Morgagni Pierantoni Azienda USL Romagna Forlì andrea.fabbri@auslromagna.it Rapid Exclusion

More information

Diagnostics guidance Published: 1 October 2014 nice.org.uk/guidance/dg15

Diagnostics guidance Published: 1 October 2014 nice.org.uk/guidance/dg15 Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, e, ARCHITECT STAT T High Sensitive Troponin-I and AccuTnI+3 assays) Diagnostics guidance

More information

International Journal of Cardiology and Cardiovascular Research Vol. 4(2), pp , September, ISSN:

International Journal of Cardiology and Cardiovascular Research Vol. 4(2), pp , September, ISSN: International Journal of Cardiology and Cardiovascular Research Vol. 4(2), pp. 072-078, September, 2018. www.premierpublishers.org, ISSN: 3102-9869 IJCCR Research Article Copeptin as a Novel Biomarker

More information

Journal of the American College of Cardiology Vol. 41, No. 3, by the American College of Cardiology Foundation ISSN /03/$30.

Journal of the American College of Cardiology Vol. 41, No. 3, by the American College of Cardiology Foundation ISSN /03/$30. Journal of the American College of Cardiology Vol. 41, No. 3, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02824-3

More information

Supplementary Table 1. Details of the components of the primary composite endpoint

Supplementary Table 1. Details of the components of the primary composite endpoint Supplementary Table 1. Details of the components of the primary composite endpoint 1. Death The cause of death will be defined by the underlying cause, not the immediate mode of death. Death will be classified

More information

Cardiac-specific troponin I (ctni) has been under intensive

Cardiac-specific troponin I (ctni) has been under intensive Original Articles Association of Mild Transient Elevation of Troponin I Levels With Increased Mortality and Major Cardiovascular Events in the General Patient Population G. Steinar Gudmundsson, MD; Stephen

More information

Improving the detection of myocardial infarction in women

Improving the detection of myocardial infarction in women Improving the detection of myocardial infarction in women British Cardiac Society Listening to the Female Voice 4 th June 2014 anoopsshah@gmail.com Dr Anoop Shah BHF Centre for Cardiovascular Sciences

More information

Acute coronary syndromes define a spectrum

Acute coronary syndromes define a spectrum Heart 2000;84:93 100 CORONARY DISEASE Acute coronary syndromes: presentation clinical spectrum and management Keith A A Fox Department of Cardiology, The Royal Infirmary, Edinburgh, UK Correspondence to:

More information

Acute coronary syndromes

Acute coronary syndromes Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.

More information

4. Which survey program does your facility use to get your program designated by the state?

4. Which survey program does your facility use to get your program designated by the state? STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI

More information

Troponin = 35. Objectives. Low Risk Chest Pain. Does this patient have ACS? Does this patient have ACS? Objectives

Troponin = 35. Objectives. Low Risk Chest Pain. Does this patient have ACS? Does this patient have ACS? Objectives Objectives Low Risk Chest Pain Jeffrey Tabas, MD Professor of Emergency Medicine Office of CME UCSF School of Medicine Improve speed and accuracy in assessing patients with possible ACS! Avoid pitfalls

More information

Ischemic Modified Albumin Predicts Critical Coronary Artery Disease in Unstable Angina Pectoris and Non-ST-Elevation Myocardial Infarction

Ischemic Modified Albumin Predicts Critical Coronary Artery Disease in Unstable Angina Pectoris and Non-ST-Elevation Myocardial Infarction Original Article J Clin Med Res. 2018;10(7):570-575 Ischemic Modified Albumin Predicts Critical Coronary Artery Disease in Unstable Angina Pectoris and Non-ST-Elevation Myocardial Infarction Abdullah Orhan

More information

Clopidogrel Date: 15 July 2008

Clopidogrel Date: 15 July 2008 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov

More information

Cardiac Bio-Marker Testing in Acute Coronary Syndromes

Cardiac Bio-Marker Testing in Acute Coronary Syndromes Cardiac Bio-Marker Testing in Acute Coronary Syndromes Dr. Zohair Alaseri, MD FRCPc, Emergency Medicine FRCPc, Critical Care Medicine Intensivest and Emergency Medicine Consultant Chairman, Department

More information